Management of Oral Herpes in Pregnant Women

Treatment Recommendations

The American College of Obstetricians and Gynecologists recommends valacyclovir 1 g orally twice daily for 7-10 days for acute episodes of oral herpes in pregnant women, with a safety profile similar to acyclovir 1, 2
The Centers for Disease Control and Prevention suggests acyclovir 400 mg orally three times daily for 7-10 days as an alternative option with equivalent safety 1, 2
Higher doses of acyclovir (400 mg orally five times daily) may be considered for severe cases, although the optimal dosing for oral herpes is unclear 3

The CDC registry findings indicate no increased risk of major birth defects after acyclovir or valacyclovir treatment compared to the general population, with a strength of evidence rated as high 1, 2
No consistent pattern of adverse pregnancy outcomes has been reported after acyclovir or valacyclovir exposure, with a strength of evidence rated as moderate 1
Both medications are considered safe throughout pregnancy, including the second and third trimesters, with a strength of evidence rated as high 1, 2

The American College of Obstetricians and Gynecologists recommends considering suppressive prophylaxis with valacyclovir 1000 mg orally twice daily or acyclovir 400 mg orally three times daily for pregnant women with frequent, severe recurrences of oral herpes, starting at 36 weeks gestation 4, 5
Suppressive therapy should be reserved for women with particularly frequent or severe recurrences that significantly impact quality of life, with a strength of evidence rated as low 4

Immunocompromised pregnant women, including those with HIV, may require higher doses of acyclovir (400 mg orally three to five times daily) and should be monitored closely, with a strength of evidence rated as moderate 1, 2
If lesions persist during standard acyclovir treatment, acyclovir resistance should be suspected and alternative therapy considered, with a strength of evidence rated as high 1, 2

Patients should be informed about the chronic nature of HSV infection with potential for recurrent episodes, and advised to avoid oral-genital contact during active oral herpes outbreaks to prevent transmission to partners 2, 3
The risk of transmission to the neonate from oral herpes is primarily through postnatal contact rather than during delivery, with a strength of evidence rated as moderate 2

In immunocompromised pregnant patients (e.g., HIV‑infected), a higher oral acyclovir regimen of 400 mg three to five times daily is recommended to achieve adequate viral suppression, reflecting CDC MMWR Recommendations and Reports guidance. 6

If genital HSV lesions persist despite standard therapy in an immunocompromised pregnant woman, clinicians should suspect acyclovir resistance and consider initiating intravenous foscarnet as an alternative treatment, per CDC MMWR Recommendations and Reports. 6